Idiopathic Inflammatory Myopathies Clinical Trial
Official title:
Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial
Idiopathic inflammatory myopathies (IIM) patients are at high risk of development of reduced bone mineral density due to impairment of functional status due to the disease and a relatively high dose of glucocorticoid use for the treatment. Reduced bone mineral density is prevalent in local IIMs patients. Denosumab and zoledronic acid are established treatments for osteoporosis in postmenopausal women and glucocorticoid-induced osteoporosis. However, the role of these treatments in reduced bone mineral density including osteoporosis and osteopenia related to IIMs are lacking. There is also no evidence on comparing the efficacy of the two agents. Therefore, the investigators conducted this prospective randomized controlled study to compare the efficacies of denosumab and zoledronic acid in treating reduced bone mineral density in IIMs patients. The hypothesis in this study is that treatment by denosumab or zoledronic acid would improve bone mineral density in IIMs patients with reduced bone mineral density.
Background:
With recent advances in diagnoses and classification of idiopathic inflammatory myopathies
(IIM), an increasing number of newly diagnosed cases of IIM is expected. These patients are
vulnerable to the development of Glucocorticoid-induced osteoporosis (GIOP) due to impaired
mobility related to musculoskeletal involvement and the relatively high doses of
glucocorticoid (GC) required for disease control. Reduced bone mineral density is prevalent
among IIM patients shown in the previous local study: osteoporosis and osteopenia are seen in
23.7% and 47.4% of IIM patients respectively. 10% of patients on long term GC treatment
sustain a fracture and up to 30-40% of patients are found to have radiological vertebral
fractures. Compared to GIOP, the treatment for patients with osteopenia is less well
addressed in current guidelines for the management of GIOP. Treatment is usually indicated in
patients with a previous history of prior low energy fracture and high fracture risks
determined by FRAX score. However, IIMs remain a rare disease entity and IIMs patients are at
particularly high risk for osteoporosis and its complications due to a relatively high dose
of steroid use and functional impairment from the disease. Therefore, traditional fracture
risks assessment tool might not be able to fully assess the fracture risks in this subgroup
of patients.
Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B
ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and
hip fracture in post-menopausal women. A recent randomized controlled trial has shown that
denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients.
Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk
osteopenia patients are not well studied. On the other hand, zoledronic acid is licensed for
the treatment of GIOP and trials found zoledronic acid improve bone mineral density at the
lumbar spine or femoral neck at 12 months of treatment. Current evidence comparing the
efficacy between denosumab and zoledronic acid is lacking.
In this prospective study, the investigators aimed to assess the efficacy of denosumab and
zoledronic acid in the treatment of IIMs patients with reduced bone mineral density.
Study methods This is a prospective open-label controlled trial. All IIMs patients followed
up in Kwong Wah Hospital are invited to participate in this study. Eligibility, inclusion,
and exclusion criteria are described in details in subsequent sessions. All included patients
will have dual-energy X-Ray absorptiometry (DEXA) scan performed at baseline. All
participants will continue calcium (1000mg daily) and vitamin D supplementation (at least 800
international unit daily). Patients with osteopenia or osteoporosis in a baseline DEXA scan
will be randomized by computer-generated blocks in 1:1 ratio into receiving denosumab
(treatment group) or zoledronic acid (controlled group). Denosumab is given at 60mg
subcutaneously every 6 months, following the FDA approved dosage. Zoledronic acid is
administered intravenously at 5mg yearly. DEXA scan will be repeated after 12 months of
treatment.
All participants will be interviewed and examined at the time of recruitment and at
subsequent follow-up visits. Patients enrolled in the study will attend follow-up visits at
least every 4 months with monitoring of adverse events associated with denosumab or
zoledronic acid use. In case of severe adverse events, treatment will be terminated, and
patients will be withdrawn from this study.
Demographic data including age, sex, ethnicity, body weight and height, menopausal status,
parity, smoking and drinking history, and comorbidities will be recorded. Diagnosis and
classification of IIM according to Bohan and Peter criteria (14) and duration of the disease
will also be documented. Details of treatment regime including dosage of GCs at time of
recruitment, cumulative GCs dosage, concomitant immunosuppressants, and medication history
will be recorded. Personal history of previous vertebral or osteoporotic fracture and
avascular necrosis will be screened. Complications related to IIMs which included
interstitial lung disease, dysphagia and malignancy and Health assessment questionnaire
disability index (HAQ-DI) at baseline will be documented. Blood results including serum
albumin level, C reactive protein (CRP), erythrocyte sedimentation rate (ESR) and creatine
kinase (CPK) will be measured at baseline and upon follow-up visits.
BMD results are recorded in terms of absolute value, T-score (Number of standard deviations
above or below mean results of young adults) and Z-score (Number of standard deviations above
or below mean results of the age-matched population). Radiographs of the thoracic and lumbar
spine will be performed at enrolment and at the completion of the study to look for vertebral
collapses. Vertebral collapse is defined as a loss of at least 25% height of vertebrae.
Fractures and new vertebral collapse during the study period will be documented.
IIMs disease activity at baseline is measured by physician's and patient's global assessment
by visual analog scale, manual muscle testing 8 (MMT8) and Myositis Disease Activity
Assessment Visual Analogue Scale (MYOACT).
BMD at the lumbar spine (L1-4), hip and femoral neck are measured by DEXA scan using Hologic
Discovery DXA system (Model: Discovery W, Hologic, Bedford, USA) The reference ranges for
T-score for Male and Female are derived from a database from the University of Hong Kong,
using matched Hong Kong Male and female data. The technicians responsible for reading DEXA
images are blinded for the details of the study.
Patients are invited to join this study from August June 2019 to December 2019. Baseline DEXA
scan and randomization will be performed within 1 month of study enrolment. Participants
would receive 12 months of treatment and DEXA scan will be repeated within 1 month upon
completion of treatment. The study and subsequent analyses will be completed by March 2021.
For the estimation in sample size, the mean baseline BMD in GIOP patients from local data is
0.87 g/cm2 with a standard deviation of 0.085 g/cm2. The expected increase in BMD after 12
months of denosumab treatment is 8% compared to placebo whereas zoledronic acid is associated
with a 6-7% increase in BMD when compared to placebo. Sample size calculated is 23 patients
in each group assuming 5% type I error and 80% power.
For statistical analysis, descriptive statistics for demographic and clinical data are
expressed as mean +/- standard deviation if they are normally distributed or as median and
range otherwise. Independent Student's t-test is used for analyzing continuous variables with
normal distribution and Chi-square test for categorical variables. Differences in BMD between
the two groups is compared with paired t-test. After adjustment of confounding factor,
analysis of covariance method (general linear model) will be done. Covariates adjusted
include age, sex, BMI, smoking and drinking status, duration of menopause in female patients,
duration of GC and cumulative dosage of GC. For assessing risk factors associated with
reduced BMD, associations between the continuous variables and BMD is assessed by Pearson's
correlation test. Univariate analysis followed by multiple linear regression model is used to
identify the independent variables for BMD. A P-value of < 0.05 is considered as
statistically significant. SPSS 25 will be used for statistical analysis.
This study is approved by the local ethical committee - Research Ethics Application (Kowloon
Central/Kowloon East) and is conducted in full accordance with the Helsinki Declaration.
Written consent is obtained from all participants. Serious adverse events will be reported to
the research and ethics committee.
This is an investigator-initiated study not supported by any pharmaceutical company. The
authors have no conflicts of interest to declare.
Outcome measures will be described in subsequent sessions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT04208464 -
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
|
Phase 2 | |
Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06316076 -
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
|
Phase 1 | |
Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
Recruiting |
NCT04792931 -
Adult Autoimmune Myopathies (MAIA)
|
N/A | |
Not yet recruiting |
NCT06417398 -
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
Not yet recruiting |
NCT06285539 -
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
|
Phase 2 | |
Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
Recruiting |
NCT05400889 -
Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies
|
Phase 2 | |
Completed |
NCT03918356 -
Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies
|
N/A | |
Completed |
NCT00341679 -
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
|
||
Recruiting |
NCT05952531 -
Characterizing Myositis With 68Ga-FAPI PET/CT
|
Early Phase 1 | |
Recruiting |
NCT05200702 -
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
Completed |
NCT03092167 -
Physical Training in Patients With Idiopathic Inflammatory Myopathies
|
N/A | |
Recruiting |
NCT03092180 -
Optimizing Treatment on Idiopathic Inflammatory Myopathies
|
||
Recruiting |
NCT05199246 -
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
|
N/A |